Johnson & Johnson Outlines Long-Term Sales Outlook with 5%-7% CAGR Expected for Innovative Medicine Portfolio Through 2030

On December 5, Johnson & Johnson announced that it would hold a meeting with the investment community at the New York Stock Exchange to introduce its overall strategy, diversified and robust pipeline of innovative pharmaceuticals and medical technologies, as well as its long-term financial outlook.

Johnson & Johnson Leaders to Highlight Key Drivers of Sustainable Competitive Growth and Value Creation

Reply "Johnson & Johnson" on the Pharma Research Network backend to receive the Johnson & Johnson Business Review PDF.

The company has unique advantages, leading the next wave of healthcare innovation through transformative science and technology.

Considering the company's confidence and strength in its future growth prospects and pipeline, Johnson & Johnson has set long-term financial goals and expectations: despite the entry of STELARA biosimilars into the U.S. market, operational sales growth is expected to be at least 3% by 2025; from 2025 to 2030, the operational sales CAGR is projected to be 5-7%.

Medical technology achieves growth through differentiated pipelines and geographic expansion. The company is expected to continue expanding into high-growth markets such as interventional cardiology, robotics, and digital, building on its leading market position.

The company forecasts that its medical technology business will increase operating sales in the high-end market, with an expected growth of 5-7% by 2027; by 2027, new product sales will account for one-third of total sales.

Innovative medicine drives continuous market growth and robust innovation, which will lead to breakthrough treatments. The company will continue to focus on highly innovative and high-growth areas while maintaining its industry-leading product pipeline.It is expected that more than 20 new drugs and over 50 product expansions will be provided by 2030.

Moreover, by 2030, Johnson & Johnson's innovative pharmaceuticals pipeline and portfolio are expected to deliver operating sales growth of 5-7% from 2025 to 2030.

More than 10 products have the potential to deliver over $5 billion in operational revenue, including the five products highlighted during the 2021 pharmaceutical business review, as well as TALVEY, TECVAYLI, and JNJ-2113;

15 varieties with sales potential of 1-5 billion dollars, including SPRAVATO, seltorexant, aticaprant, and JNJ-4804, etc.

The oncology field plans to apply for/approve 35 drugs by 2030.

https://www.investor.jnj.com/news/news-details/2023/Johnson--Johnson-Announces-Key-Drivers-for-Long-Term-Competitive-Growth-at-Enterprise-Business-Review/default.aspx